메뉴 건너뛰기




Volumn 14, Issue 1, 2015, Pages 46-57

Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis

Author keywords

Adverse drug event; Direct acting antiviral; Evidence based medicine; Protease inhibitor; Sustained virological response

Indexed keywords

BOCEPREVIR; INTERLEUKIN 6; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROLINE; RECOMBINANT PROTEIN;

EID: 84918777974     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30800-2     Document Type: Article
Times cited : (16)

References (50)
  • 4
    • 84898491795 scopus 로고    scopus 로고
    • Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: A randomized controlled trial
    • Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, Tsuji K, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat 2014; 21: 348-56.
    • (2014) J Viral Hepat , vol.21 , pp. 348-356
    • Yokoyama, S.1    Takahashi, S.2    Kawakami, Y.3    Hayes, C.N.4    Kohno, H.5    Kohno, H.6    Tsuji, K.7
  • 5
    • 84894816994 scopus 로고    scopus 로고
    • Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterfer on/ribavirin obviates a protease inhibitor
    • Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterfer on/ribavirin obviates a protease inhibitor. Hepatology 2014; 59: 71-7.
    • (2014) Hepatology , vol.59 , pp. 71-77
    • Pearlman, B.L.1    Ehleben, C.2
  • 6
    • 84891832915 scopus 로고    scopus 로고
    • Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: A meta-analysis
    • Park C, Jiang S, Lawson KA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther 2014; 39: 14-24.
    • (2014) J Clin Pharm Ther , vol.39 , pp. 14-24
    • Park, C.1    Jiang, S.2    Lawson, K.A.3
  • 7
    • 84899651307 scopus 로고    scopus 로고
    • Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
    • Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. PLoS One 2014; 9: e94542.
    • (2014) PLoS One , vol.9
    • Coppola, N.1    Pisaturo, M.2    Sagnelli, C.3    Sagnelli, E.4    Angelillo, I.F.5
  • 8
    • 84872565980 scopus 로고    scopus 로고
    • Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: A systematic review
    • Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013; 158: 114-23.
    • (2013) Ann Intern Med , vol.158 , pp. 114-123
    • Chou, R.1    Hartung, D.2    Rahman, B.3    Wasson, N.4    Cottrell, E.B.5    Fu, R.6
  • 9
    • 84904907334 scopus 로고    scopus 로고
    • Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects
    • Lawitz EJ, Membreno FE. Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects. J Gastroenterol Hepatol 2014; 29 (8): 1574-81 doi: 10.1111/jgh.12632.
    • (2014) J Gastroenterol Hepatol , vol.29 , Issue.8 , pp. 1574-1581
    • Lawitz, E.J.1    Membreno, F.E.2
  • 10
    • 33646590308 scopus 로고    scopus 로고
    • Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    • Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-60.
    • (2006) Hepatology , vol.43 , pp. 954-960
    • Jensen, D.M.1    Morgan, T.R.2    Marcellin, P.3    Pockros, P.J.4    Reddy, K.R.5    Hadziyannis, S.J.6    Ferenci, P.7
  • 13
    • 84859984959 scopus 로고    scopus 로고
    • Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark
    • Thorlund K. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark; 2011, p. 1-115.
    • (2011) User manual for trial sequential analysis (TSA). , pp. 1-115
    • Thorlund, K.1
  • 17
    • 84885475374 scopus 로고    scopus 로고
    • Telaprevir in Combination with Peginterferon Alfa- 2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results
    • Sulkowski M. Telaprevir in Combination with Peginterferon Alfa- 2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results. Hepatology 2012; 56: 1144A.
    • (2012) Hepatology , vol.56 , pp. 1144A
    • Sulkowski, M.1
  • 23
    • 84879795434 scopus 로고    scopus 로고
    • Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial
    • Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
    • (2013) Lancet Infect Dis , vol.13 , pp. 597-605
    • Sulkowski, M.1    Pol, S.2    Mallolas, J.3    Fainboim, H.4    Cooper, C.5    Slim, J.6    Rivero, A.7
  • 24
    • 83555163652 scopus 로고    scopus 로고
    • Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    • Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
    • (2012) J Hepatol , vol.56 , pp. 78-84
    • Kumada, H.1    Toyota, J.2    Okanoue, T.3    Chayama, K.4    Tsubouchi, H.5    Hayashi, N.6
  • 25
    • 84870947010 scopus 로고    scopus 로고
    • Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection
    • quiz e85
    • Flamm SL, Lawitz E, Jacobson I, Bourliere M, Hezode C, Vierling JM, Bacon BR, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013; 11: 81-87, e84; quiz e85.
    • (2013) Clin Gastroenterol Hepatol , vol.11
    • Flamm, S.L.1    Lawitz, E.2    Jacobson, I.3    Bourliere, M.4    Hezode, C.5    Vierling, J.M.6    Bacon, B.R.7
  • 26
    • 84879799809 scopus 로고    scopus 로고
    • Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial
    • Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
    • (2013) Ann Intern Med , vol.159 , pp. 86-96
    • Sulkowski, M.S.1    Sherman, K.E.2    Dieterich, D.T.3    Bsharat, M.4    Mahnke, L.5    Rockstroh, J.K.6    Gharakhanian, S.7
  • 27
    • 84890558343 scopus 로고    scopus 로고
    • Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience
    • Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.
    • (2014) J Hepatol , vol.60 , pp. 78-86
    • Coilly, A.1    Roche, B.2    Dumortier, J.3    Leroy, V.4    Botta-Fridlund, D.5    Radenne, S.6    Pageaux, G.P.7
  • 28
    • 84882908504 scopus 로고    scopus 로고
    • Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
    • Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, et al. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.
    • (2013) J Hepatol , vol.59 , pp. 434-441
    • Hezode, C.1    Fontaine, H.2    Dorival, C.3    Larrey, D.4    Zoulim, F.5    Canva, V.6    de Ledinghen, V.7
  • 30
    • 84889646106 scopus 로고    scopus 로고
    • Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort
    • Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93-103.
    • (2014) Aliment Pharmacol Ther , vol.39 , pp. 93-103
    • Backus, L.I.1    Belperio, P.S.2    Shahoumian, T.A.3    Cheung, R.4    Mole, L.A.5
  • 31
    • 84918769794 scopus 로고    scopus 로고
    • The Real Life Experience With the Development and Management of Anemia in the Era of Protease Inhibitors for Chronic Hepatitis C Infection
    • Singh G. The Real Life Experience With the Development and Management of Anemia in the Era of Protease Inhibitors for Chronic Hepatitis C Infection. Gastroenterology 2013; 144: S-1136.
    • (2013) Gastroenterology , vol.144
    • Singh, G.1
  • 32
    • 80053477775 scopus 로고    scopus 로고
    • Anemia during treatment with peginterferon alfa-2b/ ribavirin with or without boceprevir is associated with higher svr rates: Analysis of previously untreated and previous-treatment-failure patients
    • Sulkowski M. Anemia during treatment with peginterferon alfa-2b/ ribavirin with or without boceprevir is associated with higher svr rates: analysis of previously untreated and previous-treatment-failure patients. J Hepatol 2011; 54: 594.
    • (2011) J Hepatol , vol.54 , pp. 594
    • Sulkowski, M.1
  • 33
    • 84898467864 scopus 로고    scopus 로고
    • Analysis of the optimal TVR dose per weight judging from anemia during PEG-IFN/RBV/TVR combination therapy
    • Karino Y. Analysis of the optimal TVR dose per weight judging from anemia during PEG-IFN/RBV/TVR combination therapy. J Hepatol 2013; 58: S338.
    • (2013) J Hepatol , vol.58 , pp. S338
    • Karino, Y.1
  • 34
    • 84891727750 scopus 로고    scopus 로고
    • Timing and magnitude of ribavirin dose reduction (RBV DR) do not impact sustained virologic response (SVR) rates with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/RBV) in the Anemia Management Study in chronic HCV genotype 1 patients
    • Lawitz E. Timing and magnitude of ribavirin dose reduction (RBV DR) do not impact sustained virologic response (SVR) rates with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/RBV) in the Anemia Management Study in chronic HCV genotype 1 patients. Hepatology 2012; 56: 1144A.
    • (2012) Hepatology , vol.56 , pp. 1144A
    • Lawitz, E.1
  • 35
    • 84918818436 scopus 로고    scopus 로고
    • Is Week 1 (W1) and Week 2 (W2) Monitoring Helpful in Patients Treated for Chronic Hepatitis C With Pegylated Interferon, Ribavirin and a Protease Inhibitor
    • Purohit T. Is Week 1 (W1) and Week 2 (W2) Monitoring Helpful in Patients Treated for Chronic Hepatitis C With Pegylated Interferon, Ribavirin and a Protease Inhibitor. Gastroenterology 2013; 144: S983-S984.
    • (2013) Gastroenterology , vol.144 , pp. S983-S984
    • Purohit, T.1
  • 36
    • 84918773244 scopus 로고    scopus 로고
    • Serum Interleukin-6 levels during treatment correlate with resistance to Telaprevir based triple therapy in chronic hepatitis C
    • Asahina Y. Serum Interleukin-6 levels during treatment correlate with resistance to Telaprevir based triple therapy in chronic hepatitis C. J Hepatol 2013; 58: S321.
    • (2013) J Hepatol , vol.58 , pp. S321
    • Asahina, Y.1
  • 37
    • 84918837618 scopus 로고    scopus 로고
    • Impact of the viral kinetics of chronic hepatitis C patients treated with telaprevir in combination with Pegylated Interferon A2b and Ribavirin
    • Ogawa E. Impact of the viral kinetics of chronic hepatitis C patients treated with telaprevir in combination with Pegylated Interferon A2b and Ribavirin. J Hepatol 2013; 58: S-632.
    • (2013) J Hepatol , vol.58
    • Ogawa, E.1
  • 38
    • 82755182674 scopus 로고    scopus 로고
    • Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
    • Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Fuller C, Perner D, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52: 321-7.
    • (2011) J Clin Virol , vol.52 , pp. 321-327
    • Susser, S.1    Vermehren, J.2    Forestier, N.3    Welker, M.W.4    Grigorian, N.5    Fuller, C.6    Perner, D.7
  • 39
    • 84873598160 scopus 로고    scopus 로고
    • Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: A prospective longitudinal study
    • Hoffmann L, Ramos JA, Souza EV, Araujo Ramos AL, Villela- Nogueira CA, Urmenyi TP, Tanuri A, et al. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virol J 2013; 10: 57.
    • (2013) Virol J , vol.10 , pp. 57
    • Hoffmann, L.1    Ramos, J.A.2    Souza, E.V.3    Araujo Ramos, A.L.4    Villela-Nogueira, C.A.5    Urmenyi, T.P.6    Tanuri, A.7
  • 40
    • 84855223355 scopus 로고    scopus 로고
    • Long-Term Follow-Up Of Chronic Hepatitis C Infected Patients Treated With Telaprevir: Evaluation Of Persistence Of Resistant Variants By Ultra-Deep Sequencing
    • Thomas XV. Long-Term Follow-Up Of Chronic Hepatitis C Infected Patients Treated With Telaprevir: Evaluation Of Persistence Of Resistant Variants By Ultra-Deep Sequencing. J Hepatol 2011; 54: S490-S491.
    • (2011) J Hepatol , vol.54 , pp. S490-S491
    • Thomas, X.V.1
  • 41
    • 84918825148 scopus 로고    scopus 로고
    • Dynamics Of Hcv Quasispecies During Telaprevir Treatment Dissected Using Ultra-Deep Pyrosequencing: Treatment Failure In 100% Of Genotype 1a Patients
    • Pinson P. Dynamics Of Hcv Quasispecies During Telaprevir Treatment Dissected Using Ultra-Deep Pyrosequencing: Treatment Failure In 100% Of Genotype 1a Patients. J Hepatol 2012; 56: S614.
    • (2012) J Hepatol , vol.56 , pp. S614
    • Pinson, P.1
  • 42
    • 84918828884 scopus 로고    scopus 로고
    • Cross-sectional Assessment of Telaprevir and Boceprevir resistance-associated mutations of 500 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US
    • Volpe JM. Cross-sectional Assessment of Telaprevir and Boceprevir resistance-associated mutations of 500 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US. Hepatology 2012; 54: 1144A.
    • (2012) Hepatology , vol.54 , pp. 1144A
    • Volpe, J.M.1
  • 43
    • 84918829321 scopus 로고    scopus 로고
    • Timing And Characteristics Of Drug Resistance Mutations (Drms) In Chronic Hepatitis C Patients During And After Treatment With Protease Inhibitor Therapy At A Single Centre
    • Velazquez C. Timing And Characteristics Of Drug Resistance Mutations (Drms) In Chronic Hepatitis C Patients During And After Treatment With Protease Inhibitor Therapy At A Single Centre. J Hepatol 2013; 58: S632.
    • (2013) J Hepatol , vol.58 , pp. S632
    • Velazquez, C.1
  • 44
    • 84918780701 scopus 로고    scopus 로고
    • Amino Acid Change In The Positions Associated With Protease Inhibitors Resistance Is Less Frequent In Genotype 3 Than In Genotype 1 Hcv Natural Strain
    • Messina E. Amino Acid Change In The Positions Associated With Protease Inhibitors Resistance Is Less Frequent In Genotype 3 Than In Genotype 1 Hcv Natural Strain. J Hepatol 2013; 58: S632.
    • (2013) J Hepatol , vol.58 , pp. S632
    • Messina, E.1
  • 45
    • 84918835309 scopus 로고    scopus 로고
    • Clinical implications of baseline population sequencing of the NS3 protease in HCV-1 partial or null-responders to Peg-interferon/ribavirin
    • Galmozzi. Clinical implications of baseline population sequencing of the NS3 protease in HCV-1 partial or null-responders to Peg-interferon/ribavirin. Dig Liver Dis 2013; 45: S54.
    • (2013) Dig Liver Dis , vol.45 , pp. S54
    • Galmozzi1
  • 46
    • 84918817335 scopus 로고    scopus 로고
    • HCV Kinetics And Quasispecies Evolution Within The First Hours Of Telaprevir-Based Triple Therapy In Previously Treated HCV-Patients
    • Cento V. HCV Kinetics And Quasispecies Evolution Within The First Hours Of Telaprevir-Based Triple Therapy In Previously Treated HCV-Patients. J Hepatol 2013; 58: S632.
    • (2013) J Hepatol , vol.58 , pp. S632
    • Cento, V.1
  • 47
    • 84918817335 scopus 로고    scopus 로고
    • Correlation Of Early Detection Of Hcv Ns3-Resistance And Virological Failure In Patients Treated With Triple Therapy Including Telaprevir Or Boceprevir
    • Cento V. Correlation Of Early Detection Of Hcv Ns3-Resistance And Virological Failure In Patients Treated With Triple Therapy Including Telaprevir Or Boceprevir. J Hepatol 2013; 58: S632.
    • (2013) J Hepatol , vol.58 , pp. S632
    • Cento, V.1
  • 48
    • 84871853264 scopus 로고    scopus 로고
    • Host genetic variants in the pathogenesis of hepatitis C
    • Rau M, Baur K, Geier A. Host genetic variants in the pathogenesis of hepatitis C. Viruses 2012; 4: 3281-302.
    • (2012) Viruses , vol.4 , pp. 3281-3302
    • Rau, M.1    Baur, K.2    Geier, A.3
  • 49
    • 79958830099 scopus 로고    scopus 로고
    • Hepatitis C virus resistance to protease inhibitors
    • Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
    • (2011) J Hepatol , vol.55 , pp. 192-206
    • Halfon, P.1    Locarnini, S.2
  • 50
    • 84884501841 scopus 로고    scopus 로고
    • Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C
    • Leggewie M, Sreenu VB, Abdelrahman T, Leitch EC, Wilkie GS, Klymenko T, Muir D, et al. Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS 2013; 27: 2485-8.
    • (2013) AIDS , vol.27 , pp. 2485-2488
    • Leggewie, M.1    Sreenu, V.B.2    Abdelrahman, T.3    Leitch, E.C.4    Wilkie, G.S.5    Klymenko, T.6    Muir, D.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.